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A B S T R A C T   
In mouse models of dengue virus (DENV) infection, 18F-FDG PET is able to sensitively detect tissue-specific sites 
of inflammation and disease activity, as well as track therapeutic response to anti- DENV agents. However, the 
use of 18F-FDG PET to study the pathogenesis of inflammation and disease activity in DENV infection in humans, 
has not been clinically validated. Here we report the 18F-FDG PET imaging results of two patients during the 
febrile phase of acute DENV infection, paired with serial serum viral load, NS1 and proinflammatory cytokine 
measurements. Our findings demonstrate that 18F-FDG PET is able to sensitively detect and quantify organ- 
specific inflammation in the lymph nodes and spleen, in classic acute dengue fever. This raises the potential 
for 18F-FDG PET to be used as a research tool that may provide further insights into disease pathogenesis.   
We previously reported that 18F-FDG PET was able to detect dengue 
virus (DENV)-associated tissue-specific inflammation and disease ac-
tivity, as well as sensitively track therapeutic response to anti-DENV 
agents in mouse models of infection (Chacko et al., 2017). We demon-
strated that 18F-FDG uptake was most prominent in the intestines of 
AG129 mice infected with DENV, and correlated with increased virus 
load and proinflammatory cytokines, with a significant temporal trend 
of 18F-FDG uptake over the time course of infection. 18F-FDG PET was 
also able to clearly differentiate between mice treated with an antiviral 
agent and those who were treatment-naïve, as well as between lethal 
and non-lethal infections with a clinical strain of DENV2. Our 
pre-clinical findings thus raise the potential for molecular imaging 
techniques such as 18F-FDG PET to be useful as a modality not only in the 
study of dengue pathophysiology, but also to monitor response in 
dengue therapeutic trials. 
The use of 18F-FDG PET to study the pathogenesis of DENV- 
associated inflammation and disease activity in humans however, has 
not been formally and systematically validated. To date, there have only 
been two reports in the literature which describe 18F-FDG PET findings 
in patients with dengue. In both cases however, imaging was performed 
to investigate a separate clinical etiology with the diagnosis of dengue 
made coincidentally (Jinguji et al., 2016; Rittmannsberger et al., 2010). 
In order to address the current knowledge gaps in DENV pathophysi-
ology, and to obtain a visual image of human internal organs during 
acute dengue fever, we thus designed a research protocol to perform 
18F-FDG PET imaging in patients with dengue, both at the time of acute 
infection and at convalescence 3–4 weeks after recovery (see supple-
mentary material for full methods). In addition, paired serial serum 
measurement of viral load (viremia), non-structural protein 1 (NS1) and 
cytokine levels were performed each imaging time-point. Here, we 
report the findings from the first two patients. 
The study was approved by the institutional ethics review committee 
(Reference No: CIRB 2016/2252) and written informed consent was 
obtained from both patients prior to enrolment. 
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1. Patient A 
Patient A was a 45-year old female who presented with four days of 
fever, arthralgia and generalized rash. Apart from well-controlled hy-
pertension, she had no other co-morbidities. Serum dengue NS1 was 
positive (SD dengue Duo kit, Standard Diagnostics, Inc.) and a fourplex 
real-time PCR analysis (Low et al., 2014; Johnson et al., 2005) 
confirmed that the patient was infected with DENV3 (see supplementary 
material for detailed methods). Dengue IgG performed by ELISA on day 
5 of illness was positive (see supplementary material). Throughout the 
course of illness, the patient remained normotensive with no clinical 
evidence of vascular leakage, severe thrombocytopenia, or other fea-
tures suggestive of severe dengue. 
18F-FDG PET, paired with non-contrast enhanced magnetic reso-
nance imaging (MRI) for attenuation correction and anatomical local-
isation, was performed on day 5 of illness (Fig. 1). This showed increased 
metabolic uptake in multiple nodal sites including the cervical 
(maximum standardized uptake volume of 18F-FDG [SUVmax]: 5.4), 
axillary (SUVmax: 3.9), external iliac (SUVmax: 5.9), inguinal and femoral 
lymph nodes (SUVmax: 5.4). Diffuse increased metabolic uptake was also 
noted in the spleen (SUVmax: 4.5). 18F-FDG uptake in the liver was within 
normal baseline limits and there was no increased metabolic uptake seen 
in the small or large intestines. Ascites, pleural and pericardial effusions 
were not visualized. Repeat imaging performed 4 weeks later showed 
complete metabolic resolution in the lymph nodes and spleen, consistent 
with disease resolution. 
At the time of the first 18F-FDG PET scan on day 5 illness, the patient 
had quantifiable low level DENV viremia of 1.7 × 105 genome copies/ 
ml. Serum NS1 levels was 21.0 ng/ml. TNF-α level was 24.8 pg/ml, 
while serum IL-6 levels were below the detection limit of the ELISA assay 
(<10 pg/ml). As the patient had been enrolled into the study one day 
prior to undergoing 18F-FDG PET, blood sampling was also performed on 
day 4 of illness as per protocol - DENV viremia and serum NS1 levels 
were 1.3 × 106 copies/ml and 82.8 ng/ml respectively. Attempts were 
made to isolate the DENV by serially diluting the serum and infecting 
C6/36 cells (Aedes albopictus cell line), however no virus was obtained 
after three rounds of expansion, likely due to the low viremia level 
(Table 1). At the time of convalescent at week 4, both DENV viremia and 
serum NS1 levels were undetectable. These results are shown in Table 1. 
Detailed methods can be found in the supplementary materials. 
2. Patient B 
Patient B was an otherwise healthy 33-year old male who presented 
with five days of fever, myalgia and retro-orbital pain. Serum dengue 
NS1 was positive (SD dengue Duo kit, Standard Diagnostics, Inc.). 
Fourplex real-time PCR confirmed that the patient had a DENV2 infec-
tion and the dengue IgG at day 5 of illness was positive (see supple-
mentary materials for detailed methods). Similarly Patient B had an 
uncomplicated course of acute classic dengue fever. 
Patient B underwent 18F-FDG PET imaging on day 5 of acute illness, 
and at convalescence three weeks after recovery. Due to the onset of the 
COVID-19 pandemic, the study team was no longer able to travel to the 
18F-FDG PET/MRI facility located off-site. Hence, the study protocol was 
amended to pair 18F-FDG PET with unenhanced low dose computed 
tomography (18F-FDG PET/CT) (Fig. 2). Similar to Patient A, 18F-FDG 
PET/CT on day 5 showed increase 18F-FDG uptake in the cervical 
Fig. 1. 18F-FDG PET/MRI images of Patient 
A at the time of acute (Day 5 illness) and 
resolved (convalescent) DENV3 infection. 
The yellow arrows indicate sites of increased 
18F-FDG uptake in the cervical (A; maximum 
standardized uptake volume of 18F-FDG 
[SUVmax]: 5.4), axillary (B; SUVmax: 3.9), 
external iliac (D; SUVmax: 5.9), inguinal and 
femoral lymph nodes (E; SUVmax: 5.4) and 
spleen (C; SUVmax: 4.5) during acute infec-
tion. Imaging at convalescence shows meta-
bolic resolution of 18F-FDG uptake at these 
sites. 18F-FDG uptake seen in the brain, liver 
and urinary system is physiological and 
within normal expected limits.   
Table 1 
Blood sampling results.  
Day of illness  Scan 1 Scan 2 







































82.8 – 21.0 3967.9 UD UD 
Serum TNF-α 
(pg/ml) 
24.3 – 24.8 UD 17.0 UD 
Serum IL-6 
(pg/ml) 
UD – UD UD UD UD 
DENV - dengue virus; IL-6 - interleukin-6; TNF-α - tumor necrosis factor-α; UD- 
undetectable i.e. below limit of level of detection. 
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(SUVmax: 6.0), axillary (SUVmax: 3.5), external iliac (SUVmax: 3.3), 
inguinal and femoral lymph nodes (SUVmax: 2.5), and spleen (SUVmax: 
8.5). 18F-FDG uptake in the liver was within normal physiological limits, 
and again there was no evidence of pleural or pericardial effusions, or 
ascites. Repeat imaging at week 3 during convalescence showed com-
plete metabolic resolution in the lymph nodes and spleen. 
At the time of the first scan on day 5 of illness, DENV viremia and 
serum NS1 levels in Patient B were 1.3 × 108 genome copies/ml and 
3967.9 ng/ml respectively. At this level of viremia, the DENV2 virus 
isolation (see supplementary materials for details) was successful after 
three rounds of infection/expansion in C6/36 cells. Serum TNF-α and IL- 
6 levels were below the detection limit of the ELISA assay (<10 pg/ml). 
During convalescent imaging at week 3, DENV viremia, serum NS1, 
TNF-α and IL-6 levels were all undetectable. These results are shown in 
Table 1. 
Despite the small sample size, our findings raise the potential for 18F- 
FDG PET to be used as a safe and non-invasive imaging biomarker to 
detect and quantify organ-specific inflammation in acute DENV infec-
tion. Currently, only clinical serum biomarkers such as dengue viremia 
and levels of secreted (sNS1) are employed as biomarkers of infection, 
but both have limitations as endpoints in dengue therapeutic clinical 
trials (Peeling et al., 2010; Duong et al., 2011). Viral clearance in the 
blood is affected by both host and viral factors, including but not limited 
to the host immune status, DENV serotype, as well as infection status i.e. 
past exposure to a different serotypes (Tricou et al., 2010; Whitehorn 
et al., 2012; Duyen et al., 2011). Indeed, the discrepancy between 
viremia and disease outcome has been clearly demonstrated in both 
mouse models (Watanabe et al., 2015) and human clinical trials, where 
viremia reduction as a laboratory endpoint has been shown to correlate 
poorly with clinical response to treatment (Low et al., 2014; Tricou 
et al., 2010; Nguyen et al., 2013; Tam et al., 2012). Detectable DENV 
viremia in humans is also short-lived and rapidly declines from peak at 
onset to undetectable levels within 7 days of illness. Patients are often at 
the tail-end of the viremic phase by the time they are diagnosed and 
recruited into clinical trials (Tricou et al., 2011). Levels of sNS1 can also 
vary widely depending on the infection status, DENV serotype and 
timing of sampling (Duyen et al., 2011; Tricou et al., 2011). There is thus 
an urgent need to explore and develop more sensitive and clinically 
meaningful biomarkers of DENV infection, in order to effectively test 
potential anti-DENV therapeutics in the clinical trial setting. 
In both our patients, 18F-FDG uptake was most prominent in the 
lymph nodes and spleen, suggesting that inflammation and disease ac-
tivity were predominantly localised to these organs. Indeed, post- 
mortem pathologic examination of patients who died from dengue 
haemorrhagic fever have demonstrated active viral replication in similar 
organs (Kularatne et al., 2014; Rathi et al., 2013; Aye et al., 2014). The 
liver has previously been reported as a site of active viral replication and 
disease pathology in autopsy examinations of patients who died from 
severe dengue (Kularatne et al., 2014; Rathi et al., 2013; Aye et al., 
2014). However, both our patients did not show any evidence of liver 
inflammation based on lack of visualisation of increased 18F-FDG up-
take. Interestingly, our 18F-FDG PET imaging study in mouse models of 
DENV infection also did not reveal any increased 18F-FDG uptake in the 
liver (Chacko et al., 2017). This difference in observation may be due to 
the high baseline 18F-FDG uptake which normally occurs in the liver, 
making it less sensitive at detecting small increases in tissue inflam-
mation, particularly in mild disease. It is also plausible that the patho-
genesis leading to severe disease and death is different from that seen in 
mild dengue. However, this will need to be explored further with 
18F-FDG PET imaging data from a larger sample size of patients in 
various stages and severity of illness. (Zompi and Harris, 2012). 
Interestingly, our previous mouse study demonstrated increased 18F- 
FDG uptake in the small intestines but not the lymph nodes and spleen, 
contrary to the findings in our human subjects. One plausible explana-
tion is that mice in our pre-clinical study had severe lethal DENV 
infection, and hence differences in sites of 18F-FDG uptake may reflect 
true differences in pathophysiology between severe and mild dengue. 
However, it is also increasingly recognized that disease pathogenesis 
observed in mouse models of DENV infection may not accurately reflect 
human disease (Zompi and Harris, 2012), and this may also have 
accounted for the differences observed. Indeed, it is well recognized that 
the lack of a good in vivo pre-clinical infection model is one of the biggest 
challenges in DENV therapeutic development, and steps to address this 
gap with human challenge studies are underway (Yan, 2015). 
Consistent with established DENV viral and NS1 kinetics, Patient A’s 
DENV and NS1 levels fell rapidly between day 4 and 5 of illness, with a 
one-log decrease in DENV viremia as measured by quantitative real-time 
PCR over a 24 h period, and an almost 4-fold decrease in NS1 levels over 
the same time period. Additionally, both patients had either undetect-
able or only mildly elevated serum TNF-α and IL-6 levels, consistent with 
what others have reported (Kumar et al., 2012; Zhao et al., 2016). 
Nonetheless we were still able to detect significant abnormal metabolic 
activity in the lymph nodes and spleen. Although we acknowledge that it 
is not possible to completely differentiate between persistent organ 
inflammation and disease activity i.e. viral replication, using 18F-FDG 
PET, our findings are consistent with animal models of DENV infection 
Fig. 2. 18F-FDG PET/CT images of Patient B 
at the time of acute (Day 5 illness) and 
resolved (convalescent) DENV2 infection. 
The yellow arrows indicate sites of increased 
18F-FDG uptake in the cervical (A; maximum 
standardized uptake volume of 18F-FDG 
[SUVmax]: 6.0), axillary (B; SUVmax: 3.5), 
external iliac (D; SUVmax: 3.3), inguinal and 
femoral lymph nodes (E; SUVmax: 2.5), and 
spleen (C; SUVmax: 8.5) during acute infec-
tion. Imaging at convalescence shows meta-
bolic resolution of 18F-FDG uptake at these 
sites. 18F-FDG uptake seen in the brain, liver 
and urinary system is physiological and 
within normal expected limits.   
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where end-organ viral replication and pathology continue to persist 
despite falling or even undetectable levels of viremia (Chacko et al., 
2017; Watanabe et al., 2015). Our findings thus suggest that 18F-FDG 
PET is able to sensitively and non-invasively detect sites of disease ac-
tivity, highlighting the potential for this imaging modality to be used to 
track disease activity in the research setting especially beyond the peak 
febrile phase of dengue fever when both the viremia and NS1 levels are 
rapidly declining. 
We were unable to determine whether either patient had primary or 
secondary infections as we did not have blood samples earlier than day 4 
of illness. Nonetheless, as both patients had similar disease course with 
classic acute dengue fever and consistent imaging findings, this study 
provides new insight into sites of organ inflammation in dengue fever. 
Although our study was limited by lack of severe cases and lacked serial 
imaging over more time-points during the course of acute illness, we 
believe our findings show proof-of-concept that 18F-FDG PET could 
potentially be a useful research tool to define and quantify organ- 
specific inflammatory activity in acute DENV infection that may pro-
vide further insights into disease pathogenesis. Further exploratory 
validation studies on the utility of 18F-FDG PET as an imaging modality 
in other acute viral diseases are also warranted. 
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